Collegium Pharmaceutical, Inc. reports developments for a diversified biopharmaceutical business focused on commercial medicines for serious medical conditions. Its recurring news centers on JORNAY PM for ADHD, a neuropsychiatry growth business, and a responsible pain management portfolio that includes BELBUCA, Xtampza ER, Nucynta products and Symproic.
Company updates also cover operating and financial results, investor presentations, real-world data from pain medications, branded ADHD awareness campaigns, capital deployment, credit facilities, material agreements, shareholder voting matters and governance disclosures.
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) has appointed Dr. Rita Balice-Gordon to its Board of Directors, effective September 24, 2020. Dr. Balice-Gordon brings extensive scientific expertise, having served in senior roles at Muna Therapeutics and Sanofi, and as former Vice President at Pfizer. Collegium aims to enhance its leadership in responsible pain management through her insights. Management is optimistic about the contributions she will make during this significant phase in the company’s evolution.
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced five poster presentations at the 14th Annual PAINWeek National Conference held virtually from September 11-13, 2020.
The posters focused on data related to abuse and misuse of its products, including Xtampza® ER and Nucynta® ER. The findings were aimed at reinforcing the company’s commitment to responsible pain management and addressing concerns about opioid abuse. Richard Malamut, M.D., emphasized the importance of sharing real-world evidence at this scientific forum.
Collegium Pharmaceutical (Nasdaq: COLL) announced five poster presentations at the virtual 14th Annual PAINWeek National Conference from September 11-13, 2020. These presentations focus on the company's pain management products, particularly Xtampza® ER, and explore topics such as its nonmedical use, online perceptions, diversion rates, and abuse potential compared to other opioids. The conference aims to highlight critical data regarding responsible pain management practices and the risks associated with opioid use. Important safety information regarding addiction and respiratory depression is also provided.
Collegium Pharmaceutical (Nasdaq: COLL) reported strong financial results for Q2 2020, achieving a non-GAAP net income of $33.2 million and generating $43.9 million in cash from operations. Xtampza ER's net revenue rose 29% year-over-year to $33.6 million, with total prescriptions increasing by 22%. The company also added two new formulation patents for Xtampza ER, extending patent coverage to 2030 and 2036. Nucynta ER's market share reached 6.2%. Despite increased operating expenses of $31.8 million, Collegium is poised for a financially transformative year.
Collegium Pharmaceutical (Nasdaq: COLL) announced a conference call scheduled for August 5, 2020, at 4:30 p.m. ET. The call will cover the financial results for the second quarter and provide a corporate update. Interested participants can join by calling (877) 407-8037 (U.S.) or (201) 689-8037 (International) and referencing the Collegium Q2 Earnings Call. An audio webcast will also be available on the company’s website, with a replay expected to be accessible shortly after the event.
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) has been recognized as one of Boston Business Journal’s 2020 Best Places to Work. CEO Joe Ciaffoni expressed honor at the recognition, attributing it to the commitment of their talented team towards responsible pain management. The rankings are based on employee surveys evaluating work environment, job satisfaction, and more.
This acknowledgment underscores the company's efforts in creating a positive workplace culture, enhancing its reputation within the industry.
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) reported significant financial results for Q1 2020. The company achieved GAAP profitability with a net income of $0.5 million, contrasting a net loss of $9.7 million in Q1 2019. Non-GAAP net income reached $31.2 million. Xtampza ER prescriptions surged by 30% year-over-year. The company also closed the acquisition of Nucynta rights, which contributed positively to revenue growth. However, it revised its 2020 financial guidance due to COVID-19 impact, lowering expected revenues for Xtampza ER from $150-$160 million to $130-$140 million.